Prognostic Markers in Residual Tumors after neoadjuvant
chemotherapy (NACT) for Early Triple-negative Breast
Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant
GBG/AGO-B Trials
RF2-01
Neo-n (neon): three-year event-free survival and
ultrasensitive ctdna dynamics in early triple-negative breast
cancer (tnbc) treated with neoadjuvant
carboplatin/paclitaxel and nivolumab
PD7-10
Tbcrc 056: A phase 2 study of neoadjuvant niraparib with
dostarlimab for patients with BRCA- or PALB2-mutated breast
cancer: results from the TNBC cohorts
RF5-02
SABCS 2025
TRIPLE NEGATIVO
SABCS 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Impact of Immune Checkpoint Inhibition (CPI) on Fertility in
Young Women with Early Triple-Negative Breast Cancer (TNBC)
receiving neoadjuvant Chemotherapy (NACT): A Prospective
Substudy of the NSABP B-59/GBG-96-GeparDouze Trial
RF2-05
Impact of neoadjuvant pembrolizumab on ovarian function in
young patients with triple-negative breast cancer (TNBC):
Longitudinal analysis from NeoSTOP and NeoPACT trials
PD7-11
Olympian: a phase 2, multicenter, open-label study to assess the
efficacy and safety of neoadjuvant olaparib monotherapy and
olaparib plus durvalumab in patients with brca mutations and
early-stage her2-negative breast cancer
RF5-03